ClinicalTrials.gg
RecruitingNCT06432985CM_TUD_CancerUpdated Oct 2, 2026

Smoking Cessation CM for Veterans With or at Risk for Cancer

An interventional study of Focus Group and Contingency Management (CM) in Tobacco Use Disorder and Substance Use Disorder, sponsored by VA Office of Research and Development. Recruiting at 1 site in United States. Open to participants aged 18 Years and older, including healthy volunteers. Per ClinicalTrials.gov, last updated 2026-10-02.

Sponsored by VA Office of Research and Development · Not applicable, Interventional, and Treatment

How we know

From the registry’s dates

  • Started Jan 2025; still recruiting 1 year 9 months later.
Updated Oct 2, 2026Eligibility revisedInterventions changedGo to Updates ↓

Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →

Phase
Not applicable
Study type
Interventional
Enrollment
108
Allocation
Randomized
Ages
18 Years and older
Sex
All
01

Where this study stands

Counted across the records on this site · 2026-11-22

Among 17 studies in Tobacco Use Disorder by VA Office of Research and Development — 5 open to participants now, 6 under way, none of them phase 3. Tobacco Use Disorder · VA Office of Research and Development.

Planned enrollment
11th of 16
108 · median 128
Started
2025
the only one that year
No phase
10 of 17
3 open now
Registered
14th of 17
by date

Among the 17 studies in Tobacco Use Disorder by VA Office of Research and Development, this one is the 11th largest by planned enrollment of the 16 interventional ones that give a count, is the only one that started in 2025, is one of 10 with no phase, and was the 14th registered.

Tobacco Use Disorder

1,028 studies on the registry are indexed under Tobacco Use Disorder; 128 are open to participants now.

Browse Tobacco Use Disorder studies →

Open to participants now

5 of the 17 studies in Tobacco Use Disorder by VA Office of Research and Development are open now, in 1 country. Recruiting first, the newest first:

By country, each count listing its studies:

All 5 open studies →

Where they have run

Who these studies take

Of the 95 Tobacco Use Disorder studies recruiting now, 42 (44%) set no upper age limit and 50 (53%) stop at 75 or younger; 6 take children under 18; 37 take healthy volunteers.

This study: 18 Years and older · all sexes · healthy volunteers too.

The full table on the hub →

This tab as a report to print or save as PDF → With an account.

Was this useful?
Get alerts for this landscapeDownload CSVNarrow it in search →With an account: a weekly mail of what changed among 17 studies in Tobacco Use Disorder by VA Office of Research and Development, or all of them as a file.
02

Study summary

Tobacco use among US Veterans poses significant health problems and challenges to their overall well-being. The aim of this project is to evaluate the effectiveness of a program called Contingency Management (CM) in helping Veterans quit smoking during lung cancer screening or cancer care at VA clinics. CM is a behavioral treatment that uses rewards to encourage smoking cessation when verified through biological testing. In the first year, the researchers will develop a mobile CM protocol based on feedback from Veterans and healthcare staff through focus groups. In the second year, they will conduct a pilot study to test the feasibility of the mobile CM program along with counseling and medication for 20 Veterans over a five-week period. The success of the pilot study will determine whether to proceed with a larger randomized controlled trial (RCT) in years three to six, comparing the efficacy of mobile CM with standard treatment. The project will take place at SFVA.

Read the detailed description

Smoking at the time of lung cancer screening (LCS) or cancer diagnosis is associated with treatment failure, shortened lifespan, and diminished quality of life. Beyond the increased morbidity and mortality, smoking after a cancer diagnosis is associated with an estimated $3.4 billion in healthcare costs. Despite these risks, the VA does not routinely integrate smoking cessation treatment into LCS screening or cancer care, and quit rates are low.

Contingency Management (C) is a behavioral therapy approach that reinforces desired behaviors, such as smoking cessation, through the provision of tangible rewards or incentives. The goal of this Proof of Concept and Clinical Trial project is to evaluate the acceptability, feasibility, and efficacy of Contingency Management (CM) for smoking cessation among Veterans in lung cancer screening (LCS) or cancer care in Veterans Affairs (VA) clinics.

Research indicates that CM must be tailored to the clinical population and context. This staged investigation will occur in three phases. First, the investigators will conduct Focus Groups, to iteratively develop an acceptable mobile CM protocol using qualitative feedback from Veterans in VA patients in LCS or in cancer care and LCS and oncology staff. Afterward, the investigators will conduct a Pilot Study to examine the feasibility of mobile smoking cessation CM with for VA patients in LCS or in cancer care. In a single arm study, Veterans in VA LCS or cancer care will receive mobile CM plus behavioral counseling and cessation medication over 5 weeks. If successful, the investigators will conduct a Randomized Controlled Trial (RCT) to assess efficacy of mobile CM compared with treatment as usual (TAU). Veterans diagnosed with cancer or in LCS will be randomized to receive a 5-week CM condition (CM plus behavioral counseling) or TAU (referral to VA Tobacco Cessation Clinic and VA quitline). Both groups will receive pharmacotherapy.

The primary aims of this study are to develop an acceptable mobile CM protocol through qualitative feedback from Veterans and VA staff, to examine the feasibility of mobile smoking cessation CM among Veterans in LCS or cancer care through a pilot study, and to assess the efficacy of mobile CM compared to treatment as usual through a randomized controlled trial among Veterans diagnosed with cancer or in LCS.

03

Conditions studied

  • Tobacco Use Disorder
  • Substance Use Disorder

Keywords

  • Tobacco
  • Contingency Management
  • Lung Cancer
04

Who can participate

The criteria were revised on the registry on Oct 2, 2026. See what changed

Ages eligible
18 Years and older
Sexes eligible
All
Accepts healthy volunteers
Yes

Eligibility criteria

Inclusion Criteria:

In order to be eligible to participate in this study, an individual must meet all of the following criteria:

  • Human Subjects Involvement and Characteristics: This Proof of Concept and Clinical Trial has three stages. The Proof-of-Concept Phase (Years 1-2) includes a Focus Group phase (Year 1) in which the investigators will recruit both Veterans and non-Veterans (VA clinical staff); and a Pilot Study (Year 2) in which the investigators will recruit Veterans in LCS or cancer treatment at San Francisco VA Healthcare System (SFVAHCS). If the Pilot Study is successful, the investigators will recruit Veterans in lung cancer screening (LCS) or cancer treatment for the RCT (Years 3-6).
  • Focus Groups: For Focus Groups (Year 1), the investigators will recruit both Veterans and VA clinical staff at SFVAHCS.

Veterans:

  • Veteran eligible for VA healthcare
  • English-speaking
  • Received SFVAHCS cancer monitoring or treatment or lung cancer screening (LCS) within the past 24 months
  • Active cigarette smoking within the past 24 months
  • Have access to Wi-Fi and a device that supports audio and video communication

VA Clinical Staff:

  • Current member of clinical staff at the SFVAHCS
  • Have participated in the care of at least 5 VA cancer or LCS patients in the past 6 months

Pilot Feasibility Study (Year 2) and Randomized Controlled Trial

Inclusion criteria:

  • Veteran currently receiving medical care at SFVAHCS (at least one clinical visit same calendar year for cancer)
  • English-speaking
  • Current, active (same calendar year) enrollment in VA LCS, or current (same calendar year) diagnosis of cancer documented in the VA medical record, confirmed through medical record review
  • Current (past 30 days) cigarette smoking a minimum of 1 cigarette per day (average), assessed by Timeline Followback (TLFB)92, 99-101
  • Open to receiving smoking cessation interventions

Exclusion Criteria:

Focus Groups: For Focus Groups (Year 1), the investigators will recruit both Veterans and VA clinical staff at SFVAHCS.

Veterans:

Exclusion criteria: Assessed by Co-PIs' medical record review:

  • Current severe, untreated mental illness (i.e., psychosis, bipolar disorder, and/or substance use disorder (SUD) and/or
  • Current (past 30 days) active suicidal/homicidal ideation or severe behavioral instability that would prevent participation
  • Never smokers or quit smoking for longer than 36 months prior to consent (4) no access to Wi-Fi or devices that support audio and video communication

VA Clinical Staff:

Exclusion Criteria:

  • Unable to commit approximately 45-60 minutes (approx. 30-60 mins focus group/interview and self-report questionnaires)

Pilot Feasibility Study (Year 2) and Randomized Controlled Trial

Exclusion Criteria:

  • An individual who meets any of the following criteria will be excluded from participation in this study:
  • Evaluated by investigative team medical record review and clinical assessment:
  • Psychotic disorders, bipolar disorder, neurocognitive disorder, substance use disorders, or other psychiatric or medical conditions judged by the PI to be unstable in the past 30 days, based on screening results and/or medical record review, including conditions for which large sums of money would be potentially destabilizing
  • Untreated, current, active problem gambling, assessed by medical record diagnosis and/ or Problem Gambling Severity Index (PGSI) score 8
  • cancer or enrollment in end of life/ palliative care
  • Unable to commit to time commitment required for participation
  • Currently pregnant or planning to become pregnant during the study (people of ages 18-55 who are pregnant or state that they plan to become pregnant during the study)
  • A suicide attempt or suicidal ideation with intent in the 30 days prior to enrollment
  • Concurrent enrollment in a tobacco cessation clinical trial
Terms in these criteria, in plain language(2)

Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.

Metastases

Cancer that has spread from where it began to other parts of the body. “Metastatic” cancer is cancer that has spread this way.

Childbearing potential

Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).

Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.

05

Study design

Phase
Not applicable
Primary purpose
Treatment
Allocation
Randomized
Intervention model
Parallel assignment
Masking
None (open label)
Enrollment
108 participants (estimated)

Study arms

  • Other
    Focus Group

    The investigators will iteratively develop an acceptable mobile CM protocol using qualitative feedback from Veterans in VA patients in LCS or in cancer care and LCS and oncology staff.

    Behavioral: Focus Group

  • Experimental
    Contingency Management (CM)

    Veterans in VA LCS or cancer care will receive mobile CM plus behavioral counseling and cessation medication over 5 weeks.

    Behavioral: Contingency Management (CM)

  • Active comparator
    TUD Treatment as Usual (TAU)

    Participants assigned to TAU will receive time-matched Medication Management plus usual care (referral to VA Tobacco Cessation Clinic and provision of the VA Telequit quitline).

    Behavioral: Contingency Management (CM) · Behavioral: TUD Treatment as Usual (TAU)

Interventions

  • BehavioralFocus Group

    In 60-minute focus groups, participants will be categorized based on their survey responses and engaged in semi-structured discussions using open-ended questions and probes to gather detailed information. The moderators will follow best practices in qualitative research, introducing the topic of smoking cessation in the context of cancer screening and treatment and guiding the discussions from broader issues to participant-generated examples.

  • BehavioralContingency Management (CM)

    Participants will provide baseline data on their recent substance use and smoking habits and severity. They will receive a CO monitor and iCO app and will upload videos verifying smoking abstinence a minimum of once per day, 5 times per week. Financial incentives will be provided at weekly visits contingent on tobacco abstinence verified through Remote (mobile) CO monitoring. They will receive clinician feedback at the time of each CO reading, following established VA protocols for CM. Participants will also receive a 5-session smoking cessation behavioral counseling for approximately 15-20 minutes weekly. Sessions may be held by secure video conference or by telephone, per participant preference. Sessions will use CBT principles with MI incorporated for resolving reluctance to quit.

  • BehavioralTUD Treatment as Usual (TAU)

    Participants assigned to TAU will receive referral to VA Tobacco Cessation Clinic and provision of the VA Telequit quitline. The VA Tobacco Cessation Clinic is modeled after VA Tobacco Cessation Clinics across all VA facilities and involves delivery of brief counseling and pharmacotherapy for TUD if desired. VA Telequit is a national toll-free number available to Veterans that allows them to speak with a smoking cessation counselor for a recommended minimum of five sessions to develop a quit plan and receive counseling, strategies to prevent relapse, and weekly proactive follow-up calls based on National Cancer Institute guidelines.

06

What researchers measure

Primary outcomes

  1. Focus Groups

    Audio recordings will be analyzed by the research team using a template-based rapid analysis technique developed for health services research. A structured summary will be prepared, organized by topical areas drawn from the interview/focus group guide, to identify and describe themes within each topical domain.

    Time frame: Baseline

  2. Veteran Nicotine and Tobacco Use Questionnaire

    Assesses age at first use, duration of use, use of all forms of nicotine and tobacco, prior quit attempts (defined as a period of intentionally not smoking for 24 hours), duration of cessation (if any), and presence of other tobacco users in the home. It will be used in the analytic process to correlate findings/themes with characteristics.

    Time frame: Phase 1, Baseline

  3. Smoking Knowledge, Attitudes and Practices Scale (S-KAP)

    It is a validated 46 item instrument that evaluates smoking-related knowledge, beliefs, self-efficacy, cessation treatment practices, and barriers to cessation treatment delivery among healthcare providers. The scores are from the summed items. Higher scores equal more tobacco treatment and the range of scores is 0-26.

    Time frame: Phase 1, Baseline

  4. Participant Demographic Questionnaire

    Assesses age, gender identity, sexual orientation, ethnicity, race, relationship status, income, education level, military history, service-connected disability status, housing status, and employment status. It will be analyzed through bivariate associations with outcomes (attendance, rate of video uploads).

    Time frame: Phases 2 & 3, Week 0

  5. Session Attendance

    Study engagement will be assessed by tracking the number of participants attend each intervention session over the course of the 5-week intervention period. It will be analyzed through bivariate associations with participant demographics. Differences over time in measurements will be examined using generalized mixed models.

    Time frame: Phases 2 & 3, Up to 5 Weeks

  6. Remote (mobile) CO monitoring

    Study engagement will be assessed by the proportion of videos uploaded. Videos will be uploaded from Monday to Friday. It will be analyzed through bivariate associations with participant demographics. Differences over time in measurements will be examined using generalized mixed models.

    Time frame: Phases 2 & 3, Weeks 2-5

  7. Recruitment yield number of participants enrolled

    Study feasibility will be assessed by recruitment yield, i.e., tracking the number of participants who initiated treatment.

    Time frame: Phases 2 & 3, Up to 5 Weeks

  8. Study Retention

    Study retention as assessed by the number of participants that completed the study.

    Time frame: Phases 2 & 3, 5 weeks

  9. Timeline Follow-Back (TLFB): TUD medication

    Self-reported use of medication for tobacco use disorder will be assessed with TLFB, which uses a calendar with specific anchor dates to identify the quantity and frequency of use.

    Time frame: Phase 3, Weeks 0, 5, 12, 24

  10. Change in Score on the Contemplation Ladder

    The Contemplation Ladder is a visual analog comprised of 11 rungs and 5 anchor statements, representing stages of change. The response options (0) to (3) corresponded with the stage of precontemplation, (4) to (6) represented the stage of contemplation, (7) and (8) referred to the stage of preparation, (9) and (10) represented the stage of action and stage of maintenance respectively. It is a brief measure of motivation or readiness to change, where (0) is the least motivated and (10) is the most motivated. This measure has been validated for cigarette and other substance use.

    Time frame: Phase 3, Weeks 0, 5, 12, 24

  11. Changes in Nicotine and Tobacco Use Survey

    Assesses age at first use, duration of use, use of all forms of nicotine and tobacco, prior quit attempts (defined as a period of intentionally not smoking for 24 hours), duration of cessation, and presence of other tobacco users in the home and will be completed in Week 0. At Follow Ups (Weeks 5, 12 and 24), the survey will inquire about frequency and duration of quit attempts

    Time frame: Phase 3, Weeks 0, 5, 12, 24

  12. Change in Scores on the Fagerström Test for Nicotine Dependence (FTND)

    The Fagerström Test for Nicotine Dependence is a standard instrument for assessing the intensity of physical addiction to nicotine. It contains six items that evaluate the quantity of cigarette consumption, the compulsion to use, and dependence. In scoring the Fagerström Test for Nicotine Dependence, yes/no items are scored from 0 to 1 and multiple-choice items are scored from 0 to 3. The items are summed to yield a total score of 0-10. The higher the total Fagerström score, the more intense is the patient's physical dependence on nicotine.

    Time frame: Phase 3, Weeks 0, 5, 12, 24

  13. Change in Scores on the Questionnaire on Smoking Urges (QSU-Brief)

    The QSU-Brief consists of 10 statements about the respondent's feelings and thoughts about his or her desire to smoke cigarettes as he or she is completing the questionnaire (i.e., right now). Each response is scored a number ranging from 1 (strongly disagree) to 7 (strongly agree) and scores are calculated by summing the item scores. The higher the total QSU score, the more intense are the participant's smoking urges.

    Time frame: Phase 3, Weeks 0, 5, 12, 24

  14. Change in Timeline Followback (TLFB): Tobacco

    Weekly self-reported use of cigarettes will be assessed with TLFB which uses a calendar with specific anchor dates to identify the quantity and frequency of use.

    Time frame: Phase 2 Weeks 0-6; Phase 3, Weeks 0-24

  15. Change in carbon monoxide (CO) levels

    An iCO CO monitor will be used for the bio-verification of cigarette abstinence. Exhaled CO will be obtained using a study-issued iPad equipped with the iCO CO monitor and compatible app and the results will be shared through videos uploaded using VA-provided apps. Participants that report not smoking in the past 7 days and have CO levels \<6 parts per million (ppm) will be considered abstinent. For individuals with CO levels\> 6 ppm that report smoking cannabis who are not receiving NRT, salivary cotinine \<10 nanograms/ milliliter (ng/ml) will be used.

    Time frame: Phases 2- 3, Weeks 2-5

Secondary outcomes

  1. Timeline Follow-Back (TLFB): Other substances

    Self-reported use of other substances will be assessed with TLFB, which uses a calendar with specific anchor dates to identify the quantity of use.

    Time frame: Phase 2 Weeks 0-6; Phase 3, Weeks 0-24

  2. Change in Timeline Follow-Back (TLFB): TUD medication

    Self-reported use of medication for tobacco use disorder will be assessed with TLFB, which uses a calendar with specific anchor dates to identify the frequency of use.

    Time frame: Phase 2 Weeks 0-6

  3. Change in Timeline Follow-Back (TLFB): E-cigarettes

    Self-reported use of e-cigarettes will be assessed with TLFB, which uses a calendar with specific anchor dates to identify the quantity of use.

    Time frame: Phase 2 Weeks 0-6; Phase 3, Weeks 0-24

  4. Change in Timeline Follow-Back (TLFB): Other tobacco products

    Self-reported use of any other tobacco products will be assessed with TLFB, which uses a calendar with specific anchor dates to identify the quantity of use.

    Time frame: Phase 2 Weeks 0-6; Phase 3, Weeks 0-24

  5. Change in Percentage of Participants with Point Prevalent Abstinence

    Seven-day point prevalence cigarette abstinence will be defined as the percentage of participants who have reported no smoking or nicotine use on the 7 consecutive days prior to the assessment with biochemically verified cotinine levels of \< 10 nanograms/ milliliter.

    Time frame: Phase 2, Week 5; Phase 3, Weeks 5-24

  6. Mean Salivary Cotinine Levels

    Salivary Cotinine levels are an established method to biochemically verify a participant's smoking status. Participants will follow instructions provided to them in plain language describing procedures to test saliva for the presence or absence of cotinine to confirm abstinence. The cotinine test has several zones (0-6). Any result of with color in Zone 0 will be considered negative for tobacco use.

    Time frame: Phase 2 Weeks 2-6; Phase 3 Weeks 2-6, 12, and 24

07

Study locations

1 of 1 sites recruiting
08

References and documents

Individual participant data

Plan to share: No

No publications or documents are linked to this record.

09

Timeline

1 registry update since Sep 25, 2026
ElapsedEstimatedEstimated, not yet reachedSimilar studies: half by the dot; the band is the middle halfHalf of similar studies reached it by the dot; the band is the middle half, from a quarter to three quarters

Started Jan 2025 (actual). Primary completion is estimated for Aug 2031, 78 months after the start.

Of 257 non-industry interventional studies with no phase under Tobacco Use Disorder, half reached primary completion within 33 months of starting (the median), counting those still running; a quarter within 18 and three quarters within 51. This study's planned 78 months is above that.

Counting every sponsor, half of 267 studies reached it within 32 months; a quarter within 16 and three quarters within 50.

How these figures are worked out, and which studies are left out of them.

Registered
May 20, 2024
First posted
May 29, 2024
StartActual
Jan 29, 2025
Primary completionEst.
Aug 15, 2031
CompletionEst.
Sep 30, 2031
Last update
Oct 2, 2026
What these dates mean
Start.
When the first participant enrolled; while estimated, when the study expects to open to recruitment.
Primary completion.
When the last participant was examined or treated to collect data for the study's main question, its primary outcome. A study that stopped early gives the date its data collection stopped.
Completion.
When the last participant's last visit took place, for every outcome, secondary ones and side effects included: the end of the study. Often later than primary completion, sometimes the same day.
Actual and Est.
Actual means the registry says the date has happened. Est. (estimated) is a date the sponsor plans or expects. It can still move, and the sponsor is expected to change it to actual once it has passed.
Eligibility
4 criteria edited, 2 removed
What changed in the criteria
  • EditedHuman Subjects Involvement and Characteristics: This Proof of Concept and Clinical Trial has three stages. The Proof-of-Concept Phase (Years 1-2) includes a Focus Group phase (Year 1) in which the investigators will recruit both Veterans and non-Veterans (VA clinical staff); and a Pilot Study (Year 2) in which the investigators will recruit Veterans in LCS or cancer treatment at San Francisco VA Healthcare System (SFVAHCS). If the Pilot Study is successful, the investigators will recruit Veterans in lung cancer screening (LCS) or cancer treatment for the RCT (Years 3-6).
  • RemovedAge 18 years or older
  • EditedReceived SFVAHCS cancer monitoring or treatment or lung cancer screening (LCS) within the past 24 months
  • RemovedAge 18 years or older
  • EditedCurrent severe, untreated mental illness (i.e., psychosis, bipolar disorder, and/or substance use disorder (SUD)) and/or
  • EditedUnable to commit 1.5 hoursapproximately 45-60 minutes (approx. 30-60 minmins focus group/interview and self-report questionnaires)
Oct 2, 2026
Interventions
Changed Contingency Management→Contingency Management (CM). Removed Behavioral: Behavioral Counseling (Cognitive Behavioral Therapy, CBT). Arm changed Contingency Management→Contingency Management (CM); TUD Treatment as Usual→TUD Treatment as Usual (TAU)
Oct 2, 2026
Show all 1 update
  1. Oct 2, 2026
    Eligibility 4 criteria edited, 2 removed
    What changed in the criteria
    • EditedHuman Subjects Involvement and Characteristics: This Proof of Concept and Clinical Trial has three stages. The Proof-of-Concept Phase (Years 1-2) includes a Focus Group phase (Year 1) in which the investigators will recruit both Veterans and non-Veterans (VA clinical staff); and a Pilot Study (Year 2) in which the investigators will recruit Veterans in LCS or cancer treatment at San Francisco VA Healthcare System (SFVAHCS). If the Pilot Study is successful, the investigators will recruit Veterans in lung cancer screening (LCS) or cancer treatment for the RCT (Years 3-6).
    • RemovedAge 18 years or older
    • EditedReceived SFVAHCS cancer monitoring or treatment or lung cancer screening (LCS) within the past 24 months
    • RemovedAge 18 years or older
    • EditedCurrent severe, untreated mental illness (i.e., psychosis, bipolar disorder, and/or substance use disorder (SUD)) and/or
    • EditedUnable to commit 1.5 hoursapproximately 45-60 minutes (approx. 30-60 minmins focus group/interview and self-report questionnaires)
    Interventions Changed Contingency Management→Contingency Management (CM). Removed Behavioral: Behavioral Counseling (Cognitive Behavioral Therapy, CBT). Arm changed Contingency Management→Contingency Management (CM); TUD Treatment as Usual→TUD Treatment as Usual (TAU)
    + 4 other changes: index terms, identifiers, verification date and contact details

From the registry record's own update history. This site started tracking changes on Sep 25, 2026; for anything earlier, see the record history on ClinicalTrials.gov ↗

10

Registry details

Key details

Study ID
NCT06432985
Responsible party
Sponsor
First posted
May 29, 2024
Start date
Jan 29, 2025
Primary completion
Aug 15, 2031 (estimated)
Completion
Sep 30, 2031 (estimated)
Last update
Oct 2, 2026

Study contacts

Ellen Herbst, MD
Contact
Ellen.Herbst@va.gov
(415) 221-4810 ext. 24926
Madeline Martinez Rivas, PhD
Contact
madeline.martinezrivas@va.gov
(415) 221-4810 ext. 24926
Ellen Herbst, MD
principal investigator · San Francisco VA Medical Center, San Francisco, CA

Oversight

Data monitoring committee
Yes
FDA-regulated drug
No
FDA-regulated device
No
View the source record on ClinicalTrials.gov ↗

Interested in this study?

Eligibility is decided by the study team. Share this record with your doctor or contact the team directly.

Contact study team

Follow this study

Get an email when the registry record changes — status, dates, results — or when someone posts here.

Sign in to follow

Discussion

Questions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.

Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.

Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.

Start the discussion